American Oriental Bioengineering Inc. (AOB) news stock charts
American Oriental Bioengineering Inc. (AOB) Investment Summary:
American Oriental Bioengineering, Inc., together with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. It offers prescription pharmaceutical products, over-the-counter pharmaceutical products, and nutraceutical products. The company’s prescription pharmaceutical products include Shuanghuanlian Lyophilized injection powder, an anti-viral injection for the treatment of flu symptoms, upper respiratory infections, mild pneumonia, and tonsillitis; and Cease Enuresis Soft Gel to alleviate pediatric bedwetting. Its over-the-counter pharmaceutical products comprise Cease Enuresis Patch for the treatment of bedwetti...www.bioaobo.com
4,076 Employees
AMERICAN ORIENTAL BIOENGINEE (AOB:NYSE)
LAST $4.15 USD
CHANGE TODAY +0.04 0.97%
VOLUME 1.0M
As of 8:04 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of AMERICAN ORIENTAL BIOENGINEE (AOB)
|
OPEN
$4.12
|
PREVIOUS CLOSE
$4.11
|
|
|
DAY HIGH
$4.15
|
DAY LOW
$4.10
|
|
|
52 WEEK HIGH
08/3/09 - $6.38
|
52 WEEK LOW
11/24/09 - $3.72
|
|
|
MARKET CAP
325.0M
|
AVERAGE VOLUME 10 D
1.1M
|
|
|
EPS TTM
$0.55
|
SHARES OUTSTANDING
78.3M
|
|
|
AOB Does Not Pay Dividends
|
P/E TTM
7.5x
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for AMERICAN ORIENTAL BIOENGINEE (AOB)
American Oriental Bioengineering Inc. Appoints Xiaopeng Xu as Chief Operating Officer
03/17/2010
On March 11, 2010 the Board of Directors of American Oriental Bioengineering Inc. approved the appointment of Mr. Xiaopeng Xu as Chief Operating Officer of the Company. Mr. Xu will succeed Ms. Yanchun Li as the Company's Chief Operating Officer. Ms. Li will continue to serve as the Company's Chief Financial Officer and as a member of the board of directors. Since July 2009, Mr. Xu was employed by the Company as General Manager of the AOBO Pharmaceutical Industry Co. Ltd. and Mr. Xu will perform his current services pursuant to the employment agreement entered into with the Company on July 15, 2009. Such agreement may be terminated by the Company or Mr. Xu, with or without cause. Prior to joining the Company in 2009, Mr. Xu, has served in a number of senior positions in the pharmaceutical industry in China, including the General Manager of China National Pharmaceutical Industry Co. Ltd.
American Oriental Bioengineering Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009
03/15/2010
American Oriental Bioengineering Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported net income attribute to controlling interest was $11,673,108 or $0.14 per diluted share on revenues of $100,032,887 against net income attribute to controlling interest of $7,828,489 or $0.10 per diluted share on revenues of $96,270,506 for the same period last year. Income from operations was $14,898,508 against $11,593,134 for the same period last year. Income before income taxes was $15,426,922 against $9,836,237 for the same period last year. Net income was $11,673,029 against $7,856,064 for the same period last year. Comprehensive income was $12,379,746 against $7,852,963 for the same period last year. For the year, the company reported net income attribute to controlling interest was $41,421,150 or $0.53 per diluted share on revenues of $296,150,780 against net income attribute to controlling interest of $47,059,615 or $0.61 per diluted share on revenues of $264,643,058 for the same period last year. Income from operations was $58,760,095 against $63,492,506 for the same period last year. Income before income taxes was $54,519,191 against $59,722,662 for the same period last year. Net income was $41,302,205 against $47,087,190 for the same period last year. Comprehensive income was $42,783,188 against $62,827,485 for the same period last year. The company generated approximately $25.4 million of operating cash flow during the year of 2009.
American Oriental Bioengineering Inc. to Report Q4, 2009 Results on 03/15/2010
03/10/2010
American Oriental Bioengineering Inc. announced that they will report Q4, 2009 results on 03/15/2010
American Oriental Bioengineering Inc. financial resources
AOB Competitors
| Company | Last | Change |
| China Medical Technologies Inc | $14.53 USD | +0.14 |
| Harbin High-Tech Group Co | ¥7.28 CNY | +0.09 |
| Radient Pharmaceuticals Corp | $0.22 USD | -0.0051 |
| Tiens Biotech Group USA Inc | $2.47 USD | -0.08 |
| Zhuzhou Qianjin Pharmaceutical Co Ltd | ¥27.82 CNY | -0.37 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | AOB | Industry Range |
| Price/Earnings | 9.8x |
|
| Price/Sales | 1.1x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | 7.4x |
|
| TEV/Sales | 0.3x |
|
|
AOB |
||
|
AOB transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About American Oriental Bioengineering Inc.
AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme
2010-03-18 05:43:08
Quote: Item 5.02 Departure of Directors or Principal Officers;Election of Directors;
Appointment of Officers
On March 11, 2010 the Board of Directors of American Oriental Bioengineering,
Inc. approved the appointment of Mr. Xiaopeng Xu as Chief Operating Officer of
the Company. Mr. Xu will succeed Ms. Yanchun Li as the Company's Chief Operating
Officer. Ms. Li will continue to serve as the Company's Chief Financial Officer
and as a member of the board of directors.
Since July 2009, Mr. Xu was employ...Read article
American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
2010-03-17 06:45:27
Quote: Tony Liu, Chairman and Chief Executive Officer of American Oriental
Bioengineering, commented, "We are very pleased with our 2009 performance
despite the increasingly challenging economic environment worldwide and
China's rapidly changing regulatory environment.In 2009, we expanded our
product portfolio, strengthened our leading brands and diversified our
operations.Going into 2010, we'll continue to strengthen our core
competencies in production, sales and marketing and distribution reach, and
...Read article
American Oriental Bioengineering 4Q profit jumps
2010-03-17 06:45:26
Quote: NEW YORK (AP) -- Drug and nutritional product company American Oriental Bioengineering Inc. said Monday its profit climbed 49 percent in the fourth quarter due to reduced acquisition costs.The company said it earned $11.7 million, or 14 cents per share. That's up from $7.8 million, or 10 cents per share, a year ago -- a result that included $12.3 million in research and development charges related to the purchase of GuangXi HuiKe. Revenue grew 4 percent to $100 million from $96.3 million.Analyst...Read article
American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
2010-03-16 05:43:11
Quote: Tony Liu, Chairman and Chief Executive Officer of American Oriental
Bioengineering, commented, "We are very pleased with our 2009 performance
despite the increasingly challenging economic environment worldwide and
China's rapidly changing regulatory environment.In 2009, we expanded our
product portfolio, strengthened our leading brands and diversified our
operations.Going into 2010, we'll continue to strengthen our core
competencies in production, sales and marketing and distribution reach, and
...Read article
AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-K/A, Annual Report
2010-03-16 05:43:11
Quote: See " - Forward-Looking
Statements."
As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer
to American Oriental Bioengineering, Inc., a Nevada corporation.
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report contains forward-looking statements within the meaning of the
federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future...Read article
American Oriental Bioengineering 4Q profit jumps
2010-03-16 05:43:10
Quote: NEW YORK (AP) -- Drug and nutritional product company American Oriental Bioengineering Inc. said Monday its profit climbed 49 percent in the fourth quarter due to reduced acquisition costs.The company said it earned $11.7 million, or 14 cents per share. That's up from $7.8 million, or 10 cents per share, a year ago -- a result that included $12.3 million in research and development charges related to the purchase of GuangXi HuiKe. Revenue grew 4 percent to $100 million from $96.3 million.Analyst...Read article
Q4 2009 AMERICAN ORIENTAL BIOENGR INC Earnings Release - Before Market Open
2010-03-16 05:43:10
Quote: Read article
AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-Q/A, Quarterly Report
2010-03-16 05:43:09
Quote: Readers should carefully
review the risk factors disclosed in the Company's Form 10-K/A for the year
ended December 31, 2008 filed by the Company with the Securities and Exchange
Commission (SEC)..
As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer
to American Oriental Bioengineering, Inc., a Nevada corporation.
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report contains forward-looking state...Read article
American Oriental Bioengineering to Report Fourth Quarter and Full Year 2009 Financial Results on March 15, 2010
2010-03-12 03:32:49
Quote: NEW YORK, March 10NYSEAOBNews), ("the Company" or "AOBO"), a pharmaceutical
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter ("OTC")
products, today announced that it plans to release fourth quarter and full
year 2009 financial results on Monday, March 15, 2010, before the market opens.The Company will hold a conference call at 8:00 am ET on Monday, March 15http://www.bioaobo.com .A replay of th...Read article
American Oriental Bioengineering to Report Fourth Quarter and Full Year 2009 Financial Results on March 15, 2010
2010-03-11 02:32:47
Quote: NEW YORK, March 10NYSEAOBNews), ("the Company" or "AOBO"), a pharmaceutical
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter ("OTC")
products, today announced that it plans to release fourth quarter and full
year 2009 financial results on Monday, March 15, 2010, before the market opens.The Company will hold a conference call at 8:00 am ET on Monday, March 15http://www.bioaobo.com .A replay of th...Read article
Five Potential '10-Baggers' for Under $10
2010-01-28 03:06:57
Quote: The Lineup One stock to consider is American Oriental Bioengineering. Based in China, the company develops, manufactures and markets plant-based pharmaceuticals and food supplements. The company's primary product line is based on soybean peptide, which tends to lower cholesterol, blood pressure and blood fat levels. American Oriental's stock trades at about $4, and its market cap is $327 million. The Lynch strategy's most famous variable is the P/E/G ratio, which looks at the price-to-earnings ...Read article
China Aoxing Pharmaceutical Company Announces Appointment of New Chief Financial Officer
2010-01-21 02:39:16
Quote: Read article
American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog
2009-12-23 03:45:58
Quote: Read article
AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-K/A, Annual Report
2009-11-30 07:35:05
Quote: See " - Forward-Looking
Statements."
As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer
to American Oriental Bioengineering, Inc., a Nevada corporation.
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report contains forward-looking statements within the meaning of the
federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future...Read article
American Oriental Bioengineering Reports Third Quarter 2009 Financial Results
2009-11-30 07:35:05
Quote: Read article
AMERICAN ORIENTAL BIOENGINEERING INC Files SEC form 10-Q, Quarterly Report
2009-11-30 07:35:04
Quote: Readers should carefully
review the risk factors disclosed in the Company's Form 10-K/A for the year
ended December 31, 2008 filed by the Company with the Securities and Exchange
Commission (SEC)..
As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer
to American Oriental Bioengineering, Inc., a Nevada corporation.
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report contains forward-looking state...Read article
American Oriental Bioengineering 3Q profit falls
2009-11-30 07:35:04
Quote: NEW YORK (AP) -- Drug and nutritional product company American Oriental Bioengineering Inc. said Monday its profit fell 40 percent in the third quarter as its cost of sales and operating expenses jumped.The China-based company posted a profit of $10.2 million, or 13 cents per share, down from $16.9 million, or 21 cents per share, a year ago. Revenue increased 12 percent to $78.8 million from $70.6 million.Pharmaceutical product revenue rose 6 percent to $66 million while nutritional product sale...Read article
Investors Find Fat Gains in Nutrition Stocks
2009-11-30 07:35:03
Quote: Recent news in the nutrition sector helped select stocks buck the market on Tuesday.Obesity is a problem in the United States, and with a growing mainstream push for healthy living, a number of U.S.-listed nutrition stocks could see some upside.Today, isolated news is sending shares of select stocks up as much as 8% as the industry closes the gap on the S&P 500.Nutrition Product Stocks Index is up by 1.6%.It is currently lagging the S&P by -4% over the last month, however a look at the I...Read article
AMERICAN ORIENTAL BIOENGR INC Earnings Call scheduled for 8:00 am ET today
2009-11-30 07:35:03
Quote: Call DetailsAMERICAN ORIENTAL BIOENGR INC Earnings Conference Call (Q3 2009)Tue,
Nov 17, 2009, 8:00 am EasternAbout AMERICAN ORIENTAL BIOENGR INCAOB)American Oriental Bioengineering, Inc., along with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. It offers prescription and over-the-counter pharmaceutical products, and nutraceutical products. The company’s prescription pharmaceutical products include Shua...Read article
Would you like to leave a comment about American Oriental Bioengineering Inc. AOB
Find out what social network information about American Oriental Bioengineering Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides American Oriental Bioengineering Inc.'s Stock there is more great penny stock and market information at Realpennies